業績紹介

2011年 論文

  • Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125)I seeds.
    Sugawara A, Nakashima J, Kunieda E, Nagata H, Mizuno R, Seki S, Shiraishi Y, Kouta R, Oya M, Shigematsu N.
    Radiat Oncol. 2011 Oct 5;6:130.
  • [History and current review of basic research for prostate cancer].
    Kosaka T, Oya M.
    Nihon Rinsho. 2011 Jun;69 Suppl 5:7-12. Japanese.
  • Transumbilical laparo-endoscopic single site surgery for adrenal cortical adenoma inducing primary aldosteronism: initial experience.
    Miyajima A, Maeda T, Hasegawa M, Takeda T, Ishida M, Kosaka T, Kikuchi E, Nakagawa K, Oya M.
    BMC Res Notes. 2011 Sep 24;4:364.
  • [Prospective survey of erectile dysfunction after external beam radiotherapy for prostate cancer].
    Kikuchi E, Nakashima J, Ando T, Nagata H, Miyajima A, Nakagawa K, Marumo K, Oya M.
    Nihon Hinyokika Gakkai Zasshi. 2011 May;102(3):575-80. Japanese.
  • Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis.
    Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mukai M, Okada Y.
    Lab Invest. 2011 Oct;91(10):1443-58.
  • [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
    Mizuno R, Oya M.
    Gan To Kagaku Ryoho. 2011 Jul;38(7):1088-91. Japanese.
  • eko G, Kikuchi E, Matsumoto K, Obata J, Nakamura S, Miyajima A, Oya M.
    Jpn J Clin Oncol. 2011 Jul;41(7):908-14.
  • Renal cell carcinoma accompanied by left-sided IVC.
    Maeda T, Miyajima A, Kikuchi E, Oya M.
    Intern Med. 2011;50(10):1127. Epub 2011 May 1.
  • Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model.
    Matsumoto K, Kikuchi E, Horinaga M, Takeda T, Miyajima A, Nakagawa K, Oya M.
    Hum Gene Ther. 2011 Nov;22(11):1423-32.
  • [Recurrence of bladder cancer in remnant urethra and inguinal lymph node metastasis nine years after total cystectomy: a case report].
    Obata J, Kikuchi E, Kaneko G, Miyajima A, Kameyama K, Jinzaki M, Oya M.
    Nihon Hinyokika Gakkai Zasshi. 2011 Jan;102(1):34-8. Japanese.
  • Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.
    Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M.
    J Urol. 2011 Jun;185(6):2376-81.
  • Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1.
    Suda N, Shibata H, Kurihara I, Ikeda Y, Kobayashi S, Yokota K, Murai-Takeda A, Nakagawa K, Oya M, Murai M, Rainey WE, Saruta T, Itoh H.
    Endocrinology. 2011 Jun;152(6):2266-77.
  • Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma.
    Ito Y, Kikuchi E, Tanaka N, Miyajima A, Mikami S, Jinzaki M, Oya M.
    J Urol. 2011 May;185(5):1621-6.
  • Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
    Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Oya M.
    Prostate. 2011 Oct 1;71(14):1510-7.
  • Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer.
    Shirotake S, Miyajima A, Kosaka T, Tanaka N, Maeda T, Kikuchi E, Oya M.
    Urology. 2011 Apr;77(4):1009.e19-25.
  • A germ cell-specific gene, Prmt5, works in somatic cell reprogramming.
    Nagamatsu G, Kosaka T, Kawasumi M, Kinoshita T, Takubo K, Akiyama H, Sudo T, Kobayashi T, Oya M, Suda T.
    J Biol Chem. 2011 Mar 25;286(12):10641-8.
  • Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    Maeda T, Kikuchi E, Matsumoto K, Miyajima A, Oya M.
    J Urol. 2011 Mar;185(3):802-6.
  • Benefit of laparoscopic radical nephrectomy in patients with a high BMI.
    Hagiwara M, Miyajima A, Matsumoto K, Kikuchi E, Nakagawa K, Oya M.
    Jpn J Clin Oncol. 2011 Mar;41(3):400-4.
  • Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy?
    Yuge K, Kikuchi E, Matsumoto K, Takeda T, Miyajima A, Oya M.
    Jpn J Clin Oncol. 2011 Apr;41(4):565-70.
  • The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor.
    Hayakawa N, Kikuchi E, Mikami S, Matsumoto K, Miyajima A, Oya M.
    Jpn J Clin Oncol. 2011 Mar;41(3):424-9.
  • Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer.
    Tanaka N, Kikuchi E, Matsumoto K, Miyajima A, Nakagawa K, Oya M.
    J Urol. 2011 Feb;185(2):450-5.